Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like 10 Biotechs Tackling Form of Aggressive Brain Cancer July 20, 2017 Adapt Pharma Names President Of U.S. Operations April 11, 2016 NovoCure Release: Health Care Service Corporation Issues Positive Coverage Decision For Optune June 4, 2017
NovoCure Release: Health Care Service Corporation Issues Positive Coverage Decision For Optune June 4, 2017
